Protocol Ledger

NCT03646123 · Phase II · TERMINATED

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Interventional Phase II clinical trial protocol NCT03646123 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-01-28 Enrollment: 255 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03646123
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)255 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03646123
Protocol FieldVerified Registry Value
NCT IdentifierNCT03646123
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment255 participants (ACTUAL)
Registered Start Date2019-01-28
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03646123
Hospital Research SiteLocationSite Profile
Rocky Mountain Cancer Centers-AuroraAurora, COOpen Hospital Dossier ->
Florida Cancer Specialists (Saint Petersburg)Saint Petersburg, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI